Fig. 3.

BALB/c mice were sensitized and challenged according to the subchronic protocol in Fig. 2A. A dose response to drug (0.1–10 mg/kg by oral gavage 24 h before final challenge) was assessed. Anti-IL-13 antibody (0.5 ml of serum; Ref. 26) was administered intraperitoneally at 30 min before challenge and used as a known control inhibitor of the allergic response.